Fluorescent biosensors for drug discovery new tools for old targets - Screening for inhibitors of cyclin-dependent kinases

European Journal of Medicinal Chemistry

Volumn 88, Issue , 2014, Pages 74-88

  Prével, Camille ^a   Kurzawa, Laetitia ^b   Van, Thi Nhu Ngoc ^c   Morris, May C ^a  

^a CNRS   (France)

^b CEA GRENOBLE   (France)

^c University of Bordeaux   (France)

Author keywords

Cancer; CDK Cyclin; Fluorescent Biosensor; High throughput screening; Inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; AT 7519; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DINACICLIB; FLAVOPIRIDOL; ROSCOVITINE; UNCLASSIFIED DRUG; CYCLIN-DEPENDENT KINASES; PROTEIN KINASE INHIBITORS;

ARTICLE; BIOSENSOR; CANCER THERAPY; CONFORMATIONAL TRANSITION; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG TARGETING; ENZYME ACTIVITY; FLUORESCENCE; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); ANIMALS; ANTAGONISTS AND INHIBITORS; BIOSENSING TECHNIQUES; CHEMISTRY; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; METABOLISM; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALS; BIOSENSING TECHNIQUES; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; FLUORESCENCE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84911469534     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1002/cbic.201402318     Document Type: Article

References (217)

1. D.O. Morgan, Cyclin-dependent kinases: engines, clocks, and microprocessors, Annu. Rev. Cell Dev. Biol. 13 (1997) 261-291.
2. M. Malumbres, M. Barbacid, Cell cycle, CDKs and cancer: a changing paradigm, Nat. Rev. Cancer 9 (2009) 153-166.
3. M. Malumbres, Physiological relevance of cell cycle kinases, Physiol. Rev. 91 (2011) 973-1007.
4. S. Lim, P. Kaldis, Cdks, cyclins and CKIs: roles beyond cell cycle regulation, Development 140 (2013) 3079-3093.
5. M. Dorée, T. Hunt, From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J. Cell Sci. 115 (2002) 2461-2464.
6. P. Kaldis, The cdk-activating kinase (CAK): from yeast to mammals, Cell Mol. Life Sci. 55 (1999) 284-296.
7. R.P. Fisher, Secrets of a double agent: CDK7 in cell-cycle control and transcription, J. Cell Sci. 118 (2005) 5171-5180.
8. P. Aggarwal, L.P. Vaites, J.K. Kim, H. Mellert, B. Gurung, H. Nakagawa, et al., Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase, Cancer Cell 18 (2010) 329-340.
9. S.J. Tudhope, C.-C. Wang, J.L. Petrie, L. Potts, F. Malcomson, J. Kieswich, et al., A novel mechanism for regulating hepatic glycogen synthesis involving serotonin and cyclin-dependent kinase-5, Diabetes 61 (2012) 49-60.
10. X. Zhao, D. Feng, Q. Wang, A. Abdulla, X.-J. Xie, J. Zhou, et al., Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1, J. Clin. Invest. 122 (2012) 2417-2427.
11. E.A. Hanse, D.G. Mashek, J.R. Becker, A.D. Solmonson, L.K. Mullany, M.T. Mashek, et al., Cyclin D1 inhibits hepatic lipogenesis via repression of carbohydrate response element binding protein and hepatocyte nuclear factor 4a, Cell Cycle 11 (2012) 2681-2690.
12. F. Heitz, M.C. Morris, D. Fesquet, J.C. Cavadore, M. Dorée, G. Divita, Interactions of cyclins with cyclin-dependent kinases: a common interactive mechanism, Biochemistry 36 (1997) 4995-5003.
13. M. Malumbres, R. Sotillo, D. Santamaría, J. Galán, A. Cerezo, S. Ortega, et al., Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6, Cell 118 (2004) 493-504.
14. D. Santamaría, C. Barriére, A. Cerqueira, S. Hunt, C. Tardy, K. Newton, et al., Cdk1 is sufficient to drive the mammalian cell cycle, Nature 448 (2007) 811-815.
15. C.J. Sherr, J.M. Roberts, Living with or without cyclins and cyclin-dependent kinases, Genes. Dev. 18 (2004) 2699-2711.
16. D.O. Morgan, Principles of CDK regulation, Nature 374 (1995) 131-134.
17. T.R. Coleman, W.G. Dunphy, Cdc2 regulatory factors, Curr. Opin. Cell Biol. 6 (1994) 877-882.
18. R. Boutros, C. Dozier, B. Ducommun, The when and wheres of CDC25 phosphatases, Curr. Opin. Cell Biol. 18 (2006) 185-191.
19. T. Hunt, Cyclins and their partners: from a simple idea to complicated reality, Semin. Cell Biol. 2 (1991) 213-222.
20. P.D. Jeffrey, A.A. Russo, K. Polyak, E. Gibbs, J. Hurwitz, J. Massagué, et al., Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex, Nature 376 (1995) 313-320.
21. A.A. Russo, P.D. Jeffrey, N.P. Pavletich, Structural basis of cyclin-dependent kinase activation by phosphorylation, Nat. Struct. Biol. 3 (1996) 696-700.
22. N.R. Brown, M.E. Noble, A.M. Lawrie, M.C. Morris, P. Tunnah, G. Divita, et al., Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity, J. Biol. Chem. 274 (1999) 8746-8756.
23. J.C. Hagopian, M.P. Kirtley, L.M. Stevenson, R.M. Gergis, A.A. Russo, N.P. Pavletich, et al., Kinetic basis for activation of CDK2/cyclin A by phosphorylation, J. Biol. Chem. 276 (2001) 275-280.
24. M.C. Morris, C. Gondeau, J.A. Tainer, G. Divita, Kinetic mechanism of activation of the Cdk2/cyclin A complex. Key role of the C-lobe of the Cdk, J. Biol. Chem. 277 (2002) 23847-23853.
25. F. Toyoshima-Morimoto, E. Taniguchi, N. Shinya, A. Iwamatsu, E. Nishida, Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase, Nature 410 (2001) 215-220.
26. P.D. Jeffrey, L. Tong, N.P. Pavletich, Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors, Genes. Dev. 14 (2000) 3115-3125.
27. C.J. Sherr, J.M. Roberts, CDK inhibitors: positive and negative regulators of G1-phase progression, Genes. Dev. 13 (1999) 1501-1512.
28. M. Malumbres, M. Barbacid, To cycle or not to cycle: a critical decision in cancer, Nat. Rev. Cancer 1 (2001) 222-231.
29. M. Malumbres, M. Barbacid, Cell cycle kinases in cancer, Curr. Opin. Genet. Dev. 17 (2007) 60-65.
30. D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 100 (2000) 57-70.
31. M. Hall, G. Peters, Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer, Adv. Cancer Res. 68 (1996) 67-108.
32. A. Husdal, G. Bukholm, I.R.K. Bukholm, The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient, Cell Oncol. 28 (2006) 107-116.
33. A. Nar, O. Ozen, N.B. Tutuncu, B. Demirhan, Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma, Med. Oncol. 29 (2012) 294-300.
34. A. Wang, N. Yoshimi, M. Suzui, A. Yamauchi, M. Tarao, H. Mori, Different expression patterns of cyclins A, D1 and E in human colorectal cancer, J. Cancer Res. Clin. Oncol. 122 (1996) 122-126.
35. K.E. Knudsen, J.A. Diehl, C.A. Haiman, E.S. Knudsen, Cyclin D1: polymorphism, aberrant splicing and cancer risk, Oncogene 25 (2006) 1620-1628.
36. T. Suzuki, T. Urano, Y. Miki, T. Moriya, J. Akahira, T. Ishida, et al., Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor, Cancer Sci. 98 (2007) 644-651.
37. K. Aaltonen, R.M. Amini, P. Heikkila, K. Aittomaki, A. Tamminen, H. Nevanlinna, C. Blomqvist, High cyclin B1 expression is associated with poor survival in breast cancer, Br. J. Cancer 100 (2009) 1055-1060.
38. M.D. Begnami, J.H.T.G. Fregnani, S. Nonogaki, F.A. Soares, Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication, Hum. Pathol. 41 (2010) 1120-1127.
39. H. Murakami, M. Furihata, Y. Ohtsuki, S. Ogoshi, Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma, Virchows Arch. 434 (1999) 153-158.
40. J.-C. Soria, S.J. Jang, F.R. Khuri, K. Hassan, D. Liu, W.K. Hong, L. Mao, Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication, Cancer Res. 60 (2000) 4000-4004.
41. J.K. Kim, J.A. Diehl, Nuclear cyclin D1: an oncogenic driver in human cancer, J. Cell Physiol. 220 (2009) 292-296.
42. R. Van Dross, P.J. Browning, J.C. Pelling, Do truncated cyclins contribute to aberrant cyclin expression in cancer? Cell Cycle 5 (2006) 472-477.
43. J. Ekberg, C. Holm, S. Jalili, J. Richter, L. Anagnostaki, G. Landberg, et al., Expression of cyclin A1 and cell cycle proteins in hematopoietic cells and acute myeloid leukemia and links to patient outcome, Eur. J. Haematol. 75 (2005) 106-115.
44. R.M. Harwell, B.B. Mull, D.C. Porter, K. Keyomarsi, Activation of cyclindependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells, J. Biol. Chem. 279 (2004) 12695-12705.
45. R. Donnellan, R. Chetty, Cyclin E in human cancers, FASEB J. 13 (1999) 773-780.
46. A.M. Karst, P.M. Jones, N. Vena, A.H. Ligon, J.F. Liu, M.S. Hirsch, D. Etemadmoghadam, D.D.L. Bowtell, R. Drapkin, Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube e derived high-grade serous ovarian cancers, Cancer Res. (2013).
47. R.L. Huuhtanen, C.P. Blomqvist, T.O. Böhling, T.A. Wiklund, E.J. Tukiainen, M. Virolainen, B. Tribukait, L.C. Andersson, Expression of cyclin a in soft tissue sarcomas correlates with tumor aggressiveness, Cancer Res. 59 (1999) 2885-2890.
48. S. Lapenna, A. Giordano, Cell cycle kinases as therapeutic targets for cancer, Nat. Rev. Drug Discov. 8 (2009) 547-566.
49. C. Bruyére, L. Meijer, Targeting cyclin-dependent kinases in anti-neoplastic therapy, Curr. Opin. Cell Biol. 25 (2013) 772-779.
50. M.Y. Zhao, A. Auerbach, A.M. D'Costa, A.P. Rapoport, A.M. Burger, E.A. Sausville, S.A. Stass, F. Jiang, A.M. Sands, N. Aguilera, X.F. Zhao, Phosphop70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large b-cell lymphoma combination therapy, Clin. Cancer Res. 15 (2009) 1708-1720.
51. J. Yuan, A. Krämer, Y. Matthess, R. Yan, B. Spänkuch, R. Gätje, et al., Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo, Oncogene 25 (2006) 1753-1762.
52. M.C. Morris, E. Gros, G. Aldrian-Herrada, M. Choob, J. Archdeacon, F. Heitz, et al., A non-covalent peptide-based carrier for in vivo delivery of DNA mimics, Nucleic Acids Res. 35 (2007) e49.
53. I. Androic, A. Krämer, R. Yan, F. Rödel, R. Gätje, M. Kaufmann, et al., Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol, BMC Cancer 8 (2008) 391.
54. L. Crombez, M.C. Morris, S. Dufort, G. Aldrian-Herrada, Q. Nguyen, G. Mc Master, et al., Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth, Nucleic Acids Res. 37 (2009) 4559-4569.
55. Y. Chao, Y.L. Shih, J.H. Chiu, G.Y. Chau, W.Y. Lui, W.K. Yang, S.D. Lee, T.S. Huang, Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma, Cancer Res. 58 (1998) 985-990.
56. J. Wang, X. Chenivesse, B. Henglein, C. Brechot, Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma, Nature 343 (1990) 555-557.
57. E.A. Musgrove, C.E. Caldon, J. Barraclough, A. Stone, R.L. Sutherland, Cyclin D as a therapeutic target in cancer, Nat. Rev. Cancer 11 (2011) 558-572.
58. S. Ortega, M. Malumbres, M. Barbacid, Cyclin D-dependent kinases, INK4 inhibitors and cancer, Biochim. Biophys. Acta 1602 (2002) 73-87.
59. K.E. Sheppard, G.A. McArthur, The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma, Clin. Cancer Res. 19 (2013) 5320-5328.
60. O. Gautschi, D. Ratschiller, M. Gugger, D.C. Betticher, J. Heighway, Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation, Lung Cancer 55 (2007) 1-14.
61. R. Sotillo, P. Dubus, J. Martín, E. de la Cueva, S. Ortega, M. Malumbres, et al., Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors, EMBO J. 20 (2001) 6637-6647.
62. R. Sotillo, O. Renner, P. Dubus, J. Ruiz-Cabello, J. Martín-Caballero, M. Barbacid, et al., Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity, Cancer Res. 65 (2005) 3846-3852.
63. R. Chawla, J.A. Procknow, R.V. Tantravahi, J.S. Khurana, J. Litvin, E.P. Reddy, Cooperativity of Cdk4R24C and Ras in melanoma development, Cell Cycle 9 (2010) 3305-3314.
64. M. Puyol, A. Martín, P. Dubus, F. Mulero, P. Pizcueta, G. Khan, et al., A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma, Cancer Cell 18 (2010) 63-73.
65. C. Vincent-Fabert, R. Fiancette, P. Rouaud, C. Baudet, V. Truffinet, V. Magnone, et al., A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice, Am. J. Pathol. 180 (2012) 1688-1701.
66. Y. Dobashi, A. Goto, M. Fukayama, A. Abe, A. Ooi, Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma, Int. J. Cancer 110 (2004) 532-541.
67. C. Abdullah, X. Wang, D. Becker, Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma, Cell Cycle 10 (2011) 977-988.
68. H. Tsao, L. Chin, L.A. Garraway, D.E. Fisher, Melanoma: from mutations to medicine, Genes. Dev. 26 (2012) 1131-1155.
69. S.J. Vidwans, K.T. Flaherty, D.E. Fisher, J.M. Tenenbaum, M.D. Travers, J. Shrager, A melanoma molecular disease model, PLoS One 6 (2011) e18257.
70. R. Fiancette, P. Rouaud, C. Vincent-Fabert, B. Laffleur, V. Magnone, M. Cogné, et al., A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 30 regulatory region-driven c-myc transgene, J. Immunol. 187 (2011) 5772-5782.
71. E.E. Schmidt, K. Ichimura, G. Reifenberger, V.P. Collins, CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas, Cancer Res. 54 (1994) 6321-6324.
72. H.X. An, M.W. Beckmann, G. Reifenberger, H.G. Bender, D. Niederacher, Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation, Am. J. Pathol. 154 (1999) 113-118.
73. S. Park, J. Lee, I.G. Do, J. Jang, K. Rho, S. Ahn, L. Maruja, S.J. Kim, K.M. Kim, M. Mao, E. Oh, Y.J. Kim, J. Kim, Y.L. Choi, Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling, Sci. Rep. 4 (2014).
74. G. Wei, F. Lonardo, T. Ueda, T. Kim, A.G. Huvos, J.H. Healey, M. Ladanyi, CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons, Int. J. Cancer 80 (1999) 199-204.
75. J.S. Wunder, K. Eppert, S.R. Burrow, N. Gokgoz, R.S. Bell, I.L. Andrulis, N. Gogkoz, Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas, Oncogene 18 (1999) 783-788.
76. M.M. Corcoran, S.J. Mould, J.A. Orchard, R.E. Ibbotson, R.M. Chapman, A.P. Boright, C. Platt, L.C. Tsui, S.W. Scherer, D.G. Oscier, Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations, Oncogene 18 (1999) 6271-6277.
77. J.F. Costello, C. Plass, W. Arap, V.M. Chapman, W.A. Held, M.S. Berger, H.J.S. Huang, W.K. Cavenee, Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA, Cancer Res. 57 (1997) 1250-1254.
78. J.P. Brion, A.M. Couck, Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5, Am. J. Pathol. 147 (1995) 1465-1476.
79. S. Nakamura, Y. Kawamoto, S. Nakano, I. Akiguchi, J. Kimura, p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease, Acta Neuropathol. 94 (1997) 153-157.
80. H.K. Paudel, J. Lew, Z. Ali, J.H. Wang, Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments, J. Biol. Chem. 268 (1993) 23512-23518.
81. J.P. Eggers, P.M. Grandgenett, E.C. Collisson, M.E. Lewallen, J. Tremayne, P.K. Singh, et al., Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras, Clin. Cancer Res. 17 (2011) 6140-6150.
82. Z.H. Cheung, N.Y. Ip, Cdk5: a multifaceted kinase in neurodegenerative diseases, Trends Cell Biol. 22 (2012) 169-175.
83. Z. Levaque, J.L. Rosales, K.Y. Lee, Level of Cdk5 expression predicts the survival of relapsed multiple myeloma patients, Cell Cycle 11 (2012) 4093-4095.
84. Q. Liang, et al., Cdk5 is essential for TGF-b1-indiced epithelial-mesenchymal transition and breast cancer progression, Sci. Rep. 3 (2013) 1-12.
85. P. Cohen, D.R. Alessi, Kinase drug discoveryewhat's next in the field? ACS Chem. Biol. 8 (2013) 96-104.
86. H. Galons, Introduction for the special issue on kinase inhibitors, Eur. J. Med. Chem. 61 (2013) 1.
87. M.D. Garrett, A. Fattaey, CDK inhibition and cancer therapy, Curr. Opin. Genet. Dev. 9 (1999) 104-111.
88. P.M. Fischer, D.P. Lane, Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics, Curr. Med. Chem. 7 (2000) 1213-1245.
89. A.M. Senderowicz, E.A. Sausville, Preclinical and clinical development of cyclin-dependent kinase modulators, J. Natl. Cancer Inst. 92 (2000) 376-387.
90. M. Knockaert, P. Greengard, L. Meijer, Pharmacological inhibitors of cyclindependent kinases, Trends Pharmacol. Sci. 23 (2002) 417-425.
91. P.M. Fischer, J. Endicott, L. Meijer, Cyclin-dependent kinase inhibitors, Prog. Cell Cycle Res. 5 (2003) 235-248.
92. A. Huwe, R. Mazitschek, A. Giannis, Small molecules as inhibitors of cyclindependent kinases, Angew. Chem. Int. Ed. Engl. 42 (2003) 2122-2138.
93. K. Vermeulen, D.R. Van Bockstaele, Z.N. Berneman, The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer, Cell Prolif. 36 (2003) 131-149.
94. C. Benson, S. Kaye, P. Workman, M. Garrett, M. Walton, J. de Bono, Clinical anticancer drug development: targeting the cyclin-dependent kinases, Br. J. Cancer 92 (2005) 7-12.
95. G.I. Shapiro, Cyclin-dependent kinase pathways as targets for cancer treatment, J. Clin. Oncol. 24 (2006) 1770-1783.
96. G.R. Rosania, Y.-T. Chang, Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors, Expert Opin. Ther. Pat. 10 (2000) 215-230.
97. M.A. Dickson, G.K. Schwartz, Development of cell-cycle inhibitors for cancer therapy, Curr. Oncol. 16 (2009) 36-43.
98. J. Cicenas, M. Valius, The CDK inhibitors in cancer research and therapy, J. Cancer Res. Clin. Oncol. 137 (2011) 1409-1418.
99. D. Cirillo, F. Pentimalli, A. Giordano, Peptides or small molecules? Different approaches to develop more effective CDK inhibitors, Curr. Med. Chem. 18 (2011) 2854-2866.
100. A.A. Abate, F. Pentimalli, L. Esposito, A. Giordano, ATP-noncompetitive CDK inhibitors for cancer therapy: an overview, Expert Opin. Investig. Drugs 22 (2013) 895-906.
101. L. Esposito, P. Indovina, F. Magnotti, D. Conti, A. Giordano, Anticancer therapeutic strategies based on CDK inhibitors, Curr. Pharm. Des. 19 (2013) 5327-5332.
102. J. Mann, Natural products in cancer chemotherapy: past, present and future, Nat. Rev. Cancer 2 (2002) 143-148.
103. D.M. Gadbois, J.R. Hamaguchi, R.A. Swank, E.M. Bradbury, Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases, Biochem. Biophys. Res. Commun. 184 (1992) 80-85.
104. T. Tamaoki, H. Nomoto, I. Takahashi, Y. Kato, M. Morimoto, F. Tomita, Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase, Biochem. Biophys. Res. Commun. 135 (1986) 397-402.
105. N. Glab, B. Labidi, L. X Qin, C. Trehin, C. Bergounioux, L. Meijer, Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions, FEBS Lett. 353 (1994) 207-211.
106. M. Kitagawa, T. Okabe, H. Ogino, H. Matsumoto, I. Suzuki-Takahashi, T. Kokubo, et al., Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase, Oncogene 8 (1993) 2425-2432.
107. M.D. Losiewicz, B.A. Carlson, G. Kaur, E.A. Sausville, P.J. Worland, Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275, Biochem. Biophys. Res. Commun. 201 (1994) 589-595.
108. R. Hoessel, S. Leclerc, J.A. Endicott, M.E. Nobel, A. Lawrie, P. Tunnah, et al., Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases, Nat. Cell Biol. 1 (1999) 60-67.
109. C.E. Arris, F.T. Boyle, A.H. Calvert, N.J. Curtin, J.A. Endicott, E.F. Garman, A.E. Gibson, et al., Identification of novel purine and pyrimidine cyclindependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles, J. Med. Chem. 43 (2000) 2797-2804.
110. N.S. Gray, L. Wodicka, A.M. Thunnissen, T.C. Norman, S. Kwon, F.H. Espinoza, et al., Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors, Science 281 (1998) 533-538.
111. Z.A. Knight, K.M. Shokat, Chemical genetics: where genetics and pharmacology meet, Cell 128 (2007) 425-430.
112. M. Noble, P. Barrett, J. Endicott, L. Johnson, J. McDonnell, G. Robertson, et al., Exploiting structural principles to design cyclin-dependent kinase inhibitors, Biochim. Biophys. Acta 1754 (2005) 58-64.
113. C. Zhang, M.S. Lopez, A.C. Dar, E. Ladow, S. Finkbeiner, C.-H. Yun, et al., Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology, ACS Chem. Biol. 8 (2013) 1931-1938.
114. M.A. Dickson, Molecular pathways: CDK4 inhibitors for Cancer therapy, Clin. Cancer Res. 20 (2014) 3379-3383.
115. W.F. De Azevedo, S. Leclerc, L. Meijer, L. Havlicek, M. Strnad, S.H. Kim, Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine, Eur. J. Biochem. 243 (1997) 518-526.
116. Y.T. Chang, N.S. Gray, G.R. Rosania, D.P. Sutherlin, S. Kwon, T.C. Norman, et al., Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors, Chem. Biol. 6 (1999) 361-375.
117. S. Bach, M. Knockaert, J. Reinhardt, O. Lozach, S. Schmitt, B. Baratte, et al., Roscovitine targets, protein kinases and pyridoxal kinase, J. Biol. Chem. 280 (2005) 31208-31219.
118. L. Demange, F.N. Abdellah, O. Lozach, Y. Ferandin, N. Gresh, L. Meijer, et al., Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling, Bioorg. Med. Chem. Lett. 23 (2013) 125-131.
119. K. Bettayeb, N. Oumata, A. Echalier, Y. Ferandin, J.A. Endicott, H. Galons, et al., CR8, a potent and selective, roscovitine-derived inhibitor of cyclindependent kinases, Oncogene 27 (2008) 5797-5807.
120. V. Patel, A.M. Senderowicz, D. Pinto, T. Igishi, M. Raffeld, L. Quintanilla- Martinez, et al., Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis, J. Clin. Invest 102 (1998) 1674-1681.
121. A. König, G. K Schwartz, R. M Mohammad, A. Al-Katib, J. L Gabrilove, The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic b-cell leukemia lines, Blood 90 (1997) 4307-4312.
122. T.S. Lin, A.S. Ruppert, A.J. Johnson, B. Fischer, N.A. Heerema, L.A. Andritsos, et al., Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease, J. Clin. Oncol. 27 (2009) 6012-6018.
123. B.A. Christian, M.R. Grever, J.C. Byrd, T.S. Lin, Flavopiridol in the treatment of chronic lymphocytic leukemia, Curr. Opin. Oncol. 19 (2007) 573-578.
124. P.G. Wyatt, A.J. Woodhead, V. Berdini, J.A. Boulstridge, G.G. Carr, D.M. Cross, D.J. Davis, et al., Identification of N-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-Ray crystallography and structure based drug design, J. Med. Chem. 51 (2008) 4986-4999.
125. M.S. Squires, R.E. Feltell, N.G. Wallis, E.J. Lewis, D.-M. Smith, D.M. Cross, et al., Biological characterization of AT7519, a small-molecule inhibitor of cyclindependent kinases, in human tumor cell lines, Mol. Cancer Ther. 8 (2009) 324-332.
126. M.S. Squires, L. Cooke, V. Lock, W. Qi, E.J. Lewis, N.T. Thompson, J.F. Lyons, D. Mahadevan, AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples, Mol. Cancer Ther. 9 (2010) 920-928.
127. L. Santo, S. Vallet, T. Hideshima, D. Cirstea, H. Ikeda, S. Pozzi, K. Patel, Y. Okawa, G. Gorgun, G. Perrone, E. Calabrese, M. Yule, M. Squires, M. Ladetto, M. Boccadoro, P.G. Richardson, N.C. Munshi, K.C. Anderson, N. Raje, AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition, Oncogene 29 (2010) 2325-2336.
128. D. Mahadevan, R. Plummer, M.S. Squires, D. Rensvold, S. Kurtin, C. Pretzinger, T. Dragovich, J. Adams, V. Lock, D.M. Smith, D. Von Hoff, H. Calvert, A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclindependent kinase inhibitor in patients with refractory solid tumors, Ann. Oncol. 22 (2011) 2137-2143.
129. K. Paruch, M.P. Dwyer, C. Alvarez, C. Brown, T.-Y. Chan, R.J. Doll, et al., Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclindependent kinases, ACS Med. Chem. Lett. 1 (2010) 204-208.
130. D. Parry, T. Guzi, F. Shanahan, N. Davis, D. Prabhavalkar, D. Wiswell, et al., Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor, Mol. Cancer Ther. 9 (2010) 2344-2353.
131. G. Feldmann, A. Mishra, S. Bisht, C. Karikari, I. Garrido-Laguna, Z. Rasheed, et al., Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models, Cancer Biol. Ther. 12 (2011) 598-609.
132. D.W. Fry, P.J. Harvey, P.R. Keller, W.L. Elliott, M. Meade, E. Trachet, M. Albassam, X. Zheng, W.R. Leopold, N.K. Pryer, P.L. Toogood, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts, Mol. Cancer Ther. 11 (2004) 1427-1438.
133. P.L. Toogood, P.J. Harvey, J.T. Repine, D.J. Sheehan, S.N. VanderWel, H. Zhou, et al., Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6, J. Med. Chem. 48 (2005) 2388-2406.
134. L. Cen, B.L. Carlson, M.A. Schroeder, J.L. Ostrem, G.J. Kitange, A.C. Mladek, S.R. Fink, et al., p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells, Neuro Oncol. 14 (2012) 870-881.
135. M. Guha, Blockbuster dreams for Pfizer's CDK inhibitor, Nat. Biotechnol. 31 (2013) 187.
136. Z. Fang, C. Grütter, D. Rauh, Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features, ACS Chem. Biol. 8 (2013) 58-70.
137. Y. Pommier, J. Cherfils, Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery, Trends Pharmacol. Sci. 26 (2005) 138-145.
138. Y. Liu, N.S. Gray, Rational design of inhibitors that bind to inactive kinase conformations, Nat. Chem. Biol. 2 (2006) 358-364.
139. L. Pagliaro, J. Felding, K. Audouze, S.J. Nielsen, R.B. Terry, C. Krog-Jensen, et al., Emerging classes of protein-protein interaction inhibitors and new tools for their development, Curr. Opin. Chem. Biol. 8 (2004) 442-449.
140. M.R. Arkin, J.A. Wells, Small-molecule inhibitors of protein-protein interactions: progressing towards the dream, Nat. Rev. Drug Discov. 3 (2004) 301-317.
141. B.O. Villoutreix, C.M. Labbé, D. Lagorce, G. Laconde, O. Sperandio, A leap into the chemical space of protein-protein interaction inhibitors, Curr. Pharm. Des. 18 (2012) 4648-4667.
142. M.R. Arkin, M. Randal, W.L. DeLano, J. Hyde, T.N. Luong, J.D. Oslob, et al., Binding of small molecules to an adaptive protein-protein interface, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1603-1608.
143. X. Morelli, R. Bourgeas, P. Roche, Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I), Curr. Opin. Chem. Biol. 15 (2011) 475-481.
144. M.A. Bogoyevitch, R.K. Barr, A.J. Ketterman, Peptide inhibitors of protein kinases-discovery, characterisation and use, Biochim. Biophys. Acta 1754 (2005) 79-99.
145. S.K. Sharma, T.M. Ramsey, K.W. Bair, Protein-protein interactions: lessons learned, Curr. Med. Chem. Anticancer Agents 2 (2002) 311-330.
146. N. Mendoza, S. Fong, J. Marsters, H. Koeppen, R. Schwall, D. Wickramasinghe, Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth, Cancer Res. 63 (2003) 1020-1024.
147. C. Gondeau, S. Gerbal-Chaloin, P. Bello, G. Aldrian-Herrada, M.C. Morris, G. Divita, Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation, J. Biol. Chem. 280 (2005) 13793-13800.
148. N. Canela, M. Orzáez, R. Fucho, F. Mateo, R. Gutierrez, A. Pineda-Lucena, et al., Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2- cyclin A, J. Biol. Chem. 281 (2006) 35942-35953.
149. L. Bagella, A. Sun, T. Tonini, G. Abbadessa, G. Cottone, M.G. Paggi, et al., A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo, Oncogene 26 (2007) 1829-1839.
150. A. Giordano, E. Bellacchio, L. Bagella, M.G. Paggi, Interaction between the Cdk2/cyclin A complex and a small molecule derived from the pRb2/p130 spacer domain: a theoretical model, Cell Cycle 6 (2007) 2591-2593.
151. H.M. Warenius, J.D. Kilburn, J.W. Essex, R.I. Maurer, J.P. Blaydes, U. Agarwala, et al., Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of cyclin dependent kinase 4, Mol. Cancer 10 (2011) 72.
152. K.T. Chin, S.Y. Ohki, D. Tang, H.C. Cheng, J.H. Wang, M. Zhang, Identification and structure characterization of a Cdk inhibitory peptide derived from neuronal-specific Cdk5 activator, J. Biol. Chem. 274 (1999) 7120-7127.
153. Y.-L. Zheng, B.-S. Li, N.D. Amin, W. Albers, H.C. Pant, A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells, Eur. J. Biochem. 269 (2002) 4427-4434.
154. Y.-L. Zheng, S. Kesavapany, M. Gravell, R.S. Hamilton, M. Schubert, N. Amin, et al., A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons, EMBO J. 24 (2005) 209-220.
155. Y.-L. Zheng, N.D. Amin, Y.-F. Hu, P. Rudrabhatla, V. Shukla, J. Kanungo, et al., A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation, J. Biol. Chem. 285 (2010) 34202-34212.
156. V. Shukla, Y.-L. Zheng, S.K. Mishra, N.D. Amin, J. Steiner, P. Grant, et al., A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice, FASEB J. 27 (2013) 174-186.
157. J.R. Sundaram, C.P. Poore, N.H.B. Sulaimee, T. Pareek, A.B.M.A. Asad, R. Rajkumar, et al., Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo, J. Neurosci. 33 (2013) 334-343.
158. P.W. Latham, Therapeutic peptides revisited, Nat. Biotechnol. 17 (1999) 755-757.
159. I.C. Baines, P. Colas, Peptide aptamers as guides for small-molecule drug discovery, Drug Discov. Today 11 (2006) 334-341.
160. J. Zhang, P.L. Yang, N.S. Gray, Targeting cancer with small molecule kinase inhibitors, Nat. Rev. Cancer 9 (2009) 28-39.
161. B. Zhang, C. Corbel, F. Guéritte, C. Couturier, S. Bach, V.B.C. Tan, An in silico approach for the discovery of CDK5/p25 interaction inhibitors, Biotechnol. J. 6 (2011) 871-881.
162. C. Corbel, Q. Wang, H. Bousserouel, A. Hamdi, B. Zhang, O. Lozach, et al., First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors, Biotechnol. J. 6 (2011) 860-870.
163. R.M. Eglen, T. Reisine, Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors, Expert Opin. Drug Discov. 5 (2010) 277-290.
164. P. Corsino, N. Horenstein, D. Ostrov, T. Rowe, M. Law, A. Barrett, et al., A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism, J. Biol. Chem. 284 (2009) 29945-29955.
165. H. Liu, K. Liu, Z. Huang, C.M. Park, N.R. Thimmegowda, J.H. Jang, I.J. Ryoo, L. He, S.O. Kim, N. Oi, K.W. Lee, N.K. Soung, A.M. Bode, Y. Yang, X. Zhou, R.L. Erikson, J.S. Ahn, J. Hwang, K.E. Kim, Z. Dong, B.Y. Kim, A chrysin derivative suppresses skin cancer growth by inhibiting cyclin-dependent kinases, J. Biol. Chem. 288 (2013) 25924-25937.
166. S. Betzi, R. Alam, M. Martin, D.J. Lubbers, H. Han, S.R. Jakkaraj, et al., Discovery of a potential allosteric ligand binding site in CDK2, ACS Chem. Biol. 6 (2011) 492-501.
167. M.P. Martin, R. Alam, S. Betzi, D.J. Ingles, J.-Y. Zhu, E. Schönbrunn, A novel approach to the discovery of small-molecule ligands of CDK2, Chembiochem 13 (2012) 2128-2136.
168. R. Weissleder, M.J. Pittet, Imaging in the era of molecular oncology, Nature 452 (2008) 580-589.
169. J. Zhang, R.E. Campbell, A.Y. Ting, R.Y. Tsien, Creating new fluorescent probes for cell biology, Nat. Rev. Mol. Cell Biol. 3 (2002) 906-918.
170. A. Ibraheem, R.E. Campbell, Designs and applications of fluorescent proteinbased biosensors, Curr. Opin. Chem. Biol. 14 (2010) 30-36.
171. A.E. Palmer, Y. Qin, J.G. Park, J.E. McCombs, Design and application of genetically encoded biosensors, Trends Biotechnol. 29 (2011) 144-152.
172. H. Wang, E. Nakata, I. Hamachi, Recent progress in strategies for the creation of protein-based fluorescent biosensors, Chembiochem 10 (2009) 2560-2577.
173. E. Pazos, O. Vázquez, J.L. Mascareñas, M.E. Vázquez, Peptide-based fluorescent biosensors, Chem. Soc. Rev. 38 (2009) 3348-3359.
174. M.C. Morris, Fluorescent biosensors of intracellular targets from genetically encoded reporters to modular polypeptide probes, Cell Biochem. Biophys. 56 (2010) 19-37.
175. T.N.N. Van, M.C. Morris, Fluorescent sensors of protein kinases: from basics to biomedical applications, Prog. Mol. Biol. Transl. Sci. 113 (2013) 217-274.
176. J.A. Gonzalez-Vera, Probing the kinome in real time with fluorescent peptides, Chem. Soc. Rev. 41 (2012) 1652-1664.
177. M.C. Morris, Fluorescent biosensors for Cancer cell imaging and diagnostics, in: V. Preedy, J. Hunter (Eds.), Biosensors and Cancer, CRC Press, 2012, ISBN 978-1-57808-734-1.
178. M.C. Morris, Fluorescent biosensors - probing protein kinase function in Cancer and drug discovery, Biochim. Biophys. Acta 1834 (2013) 1387-1395.
179. C. Prével, M. Pellerano, T.N.N. Van, M.C. Morris, Fluorescent biosensors for high throughput screening of protein kinase inhibitors, Biotechnol. J. 9 (2014) 253-265.
180. K.A. Giuliano, D.L. Taylor, Fluorescent-protein biosensors: new tools for drug discovery, Trends Biotechnol. 16 (1998) 135-140.
181. M. Wolff, J. Wiedenmann, G.U. Nienhaus, M. Valler, et al., Novel fluorescent proteins for high-content screening, Drug Discov. Today 11 (2006) 1054-1060.
182. G.J. Zaman, A. Garritsen, T. de Boer, C.A. van Boeckel, Fluorescence assays for high-throughput screening of protein kinases, Comb. Chem. High. Throughput Screen 6 (2003) 313-320.
183. O. von Ahsen, U. Bömer, High throughput screening for kinase inhibitors, ChemBioChem 6 (2005) 481-490.
184. G.T. Hanson, B.J. Hanson, Fluorescent probes for cellular assays, Comb. Chem. High. Throughput Screen 11 (2008) 505-513.
185. P. Lang, K. Yeow, A. Nichols, A. Scheer, Cellular imaging in drug discovery, Nat. Rev. Drug Discov. 5 (2006) 343-356.
186. A.E. Carpenter, Image-based chemical screening, Nat. Chem. Biol. 3 (2007) 461-465.
187. F. Zanella, J.B. Lorens, W. Link, High content screening: seeing is believing, Trends Biotechnol. 28 (2010) 237-245.
188. M. Nobis, N.O. Carragher, E.J. McGhee, J.P. Morton, et al., Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer, Cancer Res. 73 (2013) 4674-4686.
189. A. Piljic, C. Schultz, Simultaneous recording of multiple cellular events by FRET, ACS Chem. Biol. 3 (2008) 156-160.
190. H.J. Carlson, R.E. Campbell, Genetically encoded FRET-based biosensors for multiparameter fluorescence imaging, Curr. Opin. Biotechnol. 20 (2009) 19-27.
191. C.M. Welch, H. Elliott, G. Danuser, K.M. Hahn, Imaging the coordination of multiple signalling activities in living cells, Nat. Rev. Mol. Cell Biol. 12 (2011) 749-756.
192. K.A. Giuliano, Y.T. Chen, J.R. Haskins, Positional biosensors: a new tool for high content screening, Mod. Drug Discov. 6 (2003) 33-37.
193. M.D. Allen, L.M. DiPilato, M. Rahdar, Y.R. Ren, et al., Reading dynamic kinase activity in living cells for high-throughput screening, ACS Chem. Biol. 1 (2006) 371-376.
194. J. Zhang, M.D. Allen, FRET-based biosensors for protein kinases: illuminating the kinome, Mol. Biosyst. 3 (2007) 759-765.
195. T. Mizutani, T. Kondo, S. Darmanin, M. Tsuda, et al., A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells, Clin. Cancer Res. 16 (2010) 3964-3975.
196. M.D. Shults, K.A. Janes, D.A. Lauffenburger, B. Imperiali, A multiplexed homogeneous fluorescence-based assay for protein kinase activity in cell lysates, Nat. Methods 2 (2005) 277-283.
197. M.D. Shults, D. Carrico-Moniz, B. Imperiali, Optimal Sox-based fluorescent chemosensor design for serine/threonine protein kinases, Anal. Biochem. 352 (2006) 198-207.
198. E. Luković, E. Vogel Taylor, B. Imperiali, Monitoring protein kinases in cellular media with highly selective chimeric reporters, Angew. Chem. Int. Ed. Engl. 48 (2009) 6828-6831.
199. C.I. Stains, E. Luković, B. Imperiali, A p38a-selective chemosensor for use in unfractionated cell lysates, ACS Chem. Biol. 6 (2011) 101-105.
200. C.A. Chen, R.H. Yeh, X. Yan, D.S. Lawrence, Biosensors of protein kinase action: from in vitro assays to living cells, Biochim. Biophys. Acta 1697 (2004) 39-51.
201. D.S. Lawrence, Q. Wang, Seeing is believing: peptide-based fluorescent sensors of protein tyrosine kinase activity, Chembiochem 8 (2007) 373-378.
202. V. Sharma, Q. Wang, D.S. Lawrence, Peptide-based fluorescent sensors of protein kinase activity: design and applications, Biochim. Biophys. Acta 1784 (2008) 94-99.
203. Q. Wang, E.I. Zimmerman, A. Toutchkine, T.D. Martin, et al., Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia, ACS Chem. Biol. 5 (2010) 887-895.
204. J.R. Simard, M. Getlik, C. Grütter, V. Pawar, et al., Development of a Fluorescent-tagged kinase assay system for detection and characterization of allosteric kinase inhibitors, JACS 131 (2009) 13286-13296.
205. J.R. Simard, M. Getlik, C. Grütter, R. Schneider, et al., Fluorophore labelling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations, JACS 132 (2010) 4152-4160.
206. J.R. Simard, S. Klüter, C. Grütter, M. Getlik, et al., A new screening assay for allosteric inhibitors of cSrc, Nat. Chem. Biol. 5 (2009) 394-396.
207. M. Getlik, J.R. Simard, M. Termathe, C. Grütter, et al., Fluorophore labelled kinase detects ligands that bind within the MAPK insert of p38a kinase, PLoS One 7 (2012) e39713.
208. J. Zhang, F.J. Adrian, W. Jahnke, S.W. Cowan-Jacob, et al., Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors, Nature 463 (2010) 501-506.
209. R. Schneider, R. Becker, J.R. Simard, M. Getlik, et al., Direct binding assay for the detection of type IV allosteric inhibitors of abl, JACS 134 (2012) 9138-9141.
210. J.H. Zhang, T.D. Chung, K.R. Oldenburg, A simple statistical parameter for use in evaluation and validation of high throughput screening assays, J. Biomol. Screen 4 (1999) 67-73.
211. L. Kurzawa, M. Pellerano, J.B. Coppolani, M.C. Morris, Fluorescent peptide biosensor for probing the relative abundance of cyclin-dependent kinases in living cells, PlosOne 6 (2011) e26555.
212. T.N.N. Van, M. Pellerano, S. LyKaSo, M.C. Morris, Fluorescent protein biosensor for probing CDK/cyclin activity in vitro and in living cells, ChemBioChem (2014), http://dx.doi.org/10.1002/cbic.201402318 (Epub ahead of print).
213. S. Tcherniuk, C. Perals, M. Pellerano, T.N.N. Van, E. Garcin, F. Mahuteau-Betzer, M.P. Teulade-Fichou, M.C. Morris, Allosteric inhibitors of CDK2 identified by high throughput screening with a conformation-sensitive biosensor, ACS Chem. Biol. (2014) (in revision).
214. M.C. Morris, J. Depollier, J. Mery, F. Heitz, G. Divita, A peptide carrier for the delivery of biologically active proteins into mammalian cells, Nat. Biotechnol. 19 (2001) 1173-1176.
215. W. Jahnke, M.J. Blommers, C. Fernández, C. Zwingelstein, R. Amstutz, Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors, Chembiochem 6 (2005) 1607-1610.
216. S. Klüter, C. Grütter, T. Naqvi, M. Rabiller, J.R. Simard, V. Pawar, M. Getlik, D. Rauh, Displacement assay for the detection of stabilizers of inactive kinase conformations, J. Med. Chem. 53 (2010) 357-367.
217. C.S. Lebakken, L.J. Reichling, J.M. Ellefson, S.M. Riddle, Detection of allosteric kinase inhibitors by displacement of active site probes, J. Biomol. Screen 17 (2012) 813-821.